Stock A102940 KOLON LIFE SCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kolon Life Science Inc.

Equities

A102940

KR7102940004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
22,100 KRW -0.23% Intraday chart for Kolon Life Science Inc. +0.23% -14.01%
Mar. 20 Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 05 Kolon Biotech, Inc. announced that it has received KRW 2.001 billion in funding from Kolon Life Science Inc. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 205,918 331,408 493,057 312,699 293,298
Enterprise Value (EV) 1 263,738 393,406 534,072 380,243 393,599
P/E ratio -2.23 x -7.67 x -359 x 162 x -9.55 x
Yield - - - - -
Capitalization / Revenue 1.39 x 2.56 x 2.98 x 1.63 x 2.35 x
EV / Revenue 1.78 x 3.04 x 3.23 x 1.98 x 3.16 x
EV / EBITDA -21.1 x -30.7 x 34.3 x 34.3 x -25.8 x
EV / FCF - -31,336,514 x -20,683,735 x -14,209,957 x -25,433,657 x
FCF Yield - -0% -0% -0% -0%
Price to Book 2.04 x 5.71 x 4.96 x 1.86 x 2.13 x
Nbr of stocks (in thousands) 11,408 11,408 11,400 11,412 11,412
Reference price 2 18,050 29,050 43,250 27,400 25,700
Announcement Date 3/17/21 3/17/21 3/16/22 3/20/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 148,541 129,413 165,485 192,402 124,639
EBITDA 1 -12,504 -12,806 15,549 11,096 -15,264
EBIT 1 -26,543 -25,835 4,249 1,629 -24,095
Operating Margin -17.87% -19.96% 2.57% 0.85% -19.33%
Earnings before Tax (EBT) 1 -80,197 -43,195 -4,011 2,241 -33,598
Net income 1 -92,323 -43,195 -1,375 2,133 -30,726
Net margin -62.15% -33.38% -0.83% 1.11% -24.65%
EPS 2 -8,098 -3,789 -120.6 169.0 -2,692
Free Cash Flow - -12,554 -25,821 -26,759 -15,476
FCF margin - -9.7% -15.6% -13.91% -12.42%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/17/21 3/17/21 3/16/22 3/20/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 57,820 61,998 41,015 67,545 100,301
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -4.624 x -4.841 x 2.638 x 6.087 x -6.571 x
Free Cash Flow - -12,554 -25,821 -26,759 -15,476
ROE (net income / shareholders' equity) - -54.3% -1.75% 1.6% -22%
ROA (Net income/ Total Assets) - -6.13% 1.1% 0.37% -4.83%
Assets 1 - 704,400 -125,038 574,863 636,143
Book Value Per Share 2 8,861 5,084 8,720 14,697 12,063
Cash Flow per Share 2 519.0 1,316 2,439 558.0 663.0
Capex 1 30,779 2,743 4,413 6,305 10,144
Capex / Sales 20.72% 2.12% 2.67% 3.28% 8.14%
Announcement Date 3/17/21 3/17/21 3/16/22 3/20/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KOLON LIFE SCIENCE INC. Stock Kolon Life Science Inc.
-14.01% 186M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A102940 Stock
  4. Financials Kolon Life Science Inc.